Tourmaline Bio Inc
Company Profile
Business description
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
Contact
27 West 24th Street
Suite 702
New YorkNY10010
USAT: +1 646 481-9832
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
74
Stocks News & Analysis
stocks
Potentially catastrophic ruling for ASX company
stocks
4 charts on Nvidia’s record $4 trillion market cap
stocks
Could merger breathe new life into struggling ASX asset manager?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,852.10 | 36.80 | 0.42% |
CAC 40 | 7,808.17 | 21.12 | -0.27% |
DAX 40 | 24,160.64 | 94.67 | -0.39% |
Dow JONES (US) | 44,459.65 | 88.14 | 0.20% |
FTSE 100 | 8,998.06 | 56.94 | 0.64% |
HKSE | 24,203.32 | 63.75 | 0.26% |
NASDAQ | 20,640.33 | 54.80 | 0.27% |
Nikkei 225 | 39,446.09 | 13.53 | -0.03% |
NZX 50 Index | 12,676.16 | 2.53 | -0.02% |
S&P 500 | 6,268.56 | 8.81 | 0.14% |
S&P/ASX 200 | 8,609.00 | 38.60 | 0.45% |
SSE Composite Index | 3,519.65 | 9.47 | 0.27% |